Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
1d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback